|Traded as||NASDAQ: INCY|
S&P 500 Component
|Hervé Hoppenot (President and CEO, 2014)|
|Revenue||$US 1.5 billion (2017)|
|$US (313) million (2017)|
|Total assets||$US 1.504 billion (2017)|
|Total equity||$US 1.632 billion (2017)|
Number of employees
|Footnotes / references|
As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly. It gained EU approval in February 2017. In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).
In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.
In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys. On March 3, 2020, the agreement received antitrust clearance and thus became effective.
- Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". delawareonline.com. Retrieved 2 Mar 2015.
- Incyte Corporation (2012), Form 10-K (SEC filing), Incyte Corporation (published February 22, 2012), Commission File Number: 0-27488, archived from the original on January 26, 2013, retrieved May 6, 2012
- Natoli, Cori Anne (May 5, 2012), "Incyte looks to ride on drug's success", The News Journal, retrieved May 6, 2012
- "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Archived from the original on 8 March 2015. Retrieved 2 Mar 2015.
- "Baricitinib" (pdf). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
- Ramsey, L (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.
- Grant, Ch (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.
- Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European journal of cancer (Oxford, England : 1990). 76: 167–182. doi:10.1016/j.ejca.2017.01.011. PMID 28324751.
- Tracy Staton (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.
- "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. Retrieved 2015-12-29.
- "People". Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 41.
- "Incyte to Co-Develop Hengrui's SHR-1210 in Up-to-$795M+ Deal". Genetic Engineering & Biotechnology News. 2 September 2015.
- "MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab".
- "MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab".
- Business data for Incyte: